

Efficacy and safety of lower versus higher CO₂ extraction devices to allow ultraprotective ventilation: secondary analysis of the SUPERNOVA study

Alain Combes,¹ Tommaso Tonetti,² Vito Fanelli,³ Tai Pham,⁴ Antonio Pesenti,^{5,6} Jordi Mancebo,⁷ Daniel Brodie,⁸ V Marco Ranieri⁹

¹Hôpital Universitaire Pitié Salpêtrière, Paris, France
²Department of Anesthesiology, Georg-August-Universität Göttingen, Göttingen, Germany
³Università degli Studi di Torino, Turin, Italy
⁴Hôpital Tenon, Unité de Réanimation médico-chirurgicale, Pôle Thorax Voies aériennes, Assistance Publique—Hôpitaux de Paris, Paris, France
⁵Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy
⁶Department of Anesthesia, Critical Care and Emergency, La Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy
⁷Hospital de la Santa Creu i Sant Pau Institut de Recerca, Barcelona, Spain
⁸New York-Presbyterian Hospital/Columbia University Medical Center, New York City, New York, USA
⁹Policlinico di Sant'Orsola, Anesthesia and Intensive Care Medicine, Università degli Studi di Bologna, Bologna, Italy

Correspondence to

Professor V Marco Ranieri, Policlinico di Sant'Orsola, Anesthesia and Intensive Care Medicine, Università degli Studi di Bologna, Bologna, Italy; m.ranieri@unibo.it

Received 16 May 2019
 Revised 11 June 2019
 Accepted 5 July 2019
 Published Online First 13 August 2019



© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Combes A, Tonetti T, Fanelli V, et al. *Thorax* 2019;**74**:1179–1181.

ABSTRACT

Retrospective analysis of the SUPERNOVA trial exploring the hypothesis that efficacy and safety of extracorporeal carbon dioxide removal (ECCO₂R) to facilitate reduction of tidal volume (V_T) to 4 mL/kg in patients with acute respiratory distress syndrome (ARDS) may differ between systems with *lower* (area of membrane length 0.59 m²; blood flow 300–500 mL/min) and *higher* (membrane area 1.30 m²; blood flow between 800 and 1000 mL/min) CO₂ extraction capacity. Ninety-five patients with moderate ARDS were included (33 patients treated with *lower* and 62 patients treated with *higher* CO₂ extraction devices). We found that (1) V_T of 4 mL/kg was reached by 55% and 64% of patients with the lower extraction versus 90% and 92% of patients with higher extraction devices at 8 and 24 hours from baseline, respectively (p<0.001), and (2) percentage of patients experiencing episodes of ECCO₂R-related haemolysis and bleeding was higher with *lower* than with *higher* extraction devices (21% vs 6%, p=0.045% and 27% vs 6%, p=0.010, respectively). Although V_T of 4 mL/kg could have been obtained with all devices, this was achieved frequently and with a lower rate of adverse events by devices with *higher* CO₂ extraction capacity.

INTRODUCTION

Reduction of tidal volume (V_T) to 3–4 mL/kg of predicted body weight (PBW) and of end-inspiratory plateau pressure (P_{PLAT}) to ≤25 cmH₂O integrated by extracorporeal carbon dioxide removal (ECCO₂R) has been proposed in patients with acute respiratory distress syndrome (ARDS).¹

We recently reported results of the SUPERNOVA trial, a phase II study that assessed feasibility and safety of ECCO₂R in patients with moderate ARDS.² The study was conducted using *lower* (cross-sectional area of membrane lung 0.59 m², blood flow 300–500 mL/min; Hemolung, ALung Technologies, Pittsburgh, Pennsylvania, USA) and *higher* (cross-sectional area of membrane lung 1.30 m², blood flow between 800 and 1000 mL/min; iLA, Novalung, Heilbronn, Germany and Cardiohelp, Getinge, Rastatt, Germany) CO₂ extraction devices.² We perform a retrospective analysis of the SUPERNOVA trial to explore the hypothesis that efficacy and safety of ECCO₂R to allow V_T of 4 mL/kg and P_{PLAT} ≤25 of cmH₂O may vary between *lower* vs *higher* CO₂ extraction devices.

METHODS

Patients older than 18 years with moderate ARDS³ were included. Inclusion and exclusion criteria have been previously reported.²

V_T and positive end-expiratory pressure (PEEP) were in September as previously described (base-line).⁴ V_T was reduced to 4 mL/kg PBW, titrating PEEP to target P_{PLAT} of 23–25 cmH₂O and ECCO₂R hence was initiated.

Effectiveness was assessed as the proportion of patients who achieved a V_T of 4 mL/kg with PaCO₂ not increasing more than 20% from base-line (with arterial pH >7.30). Safety was assessed as the number of patients experiencing severe and ECCO₂R-related adverse events. Physiological variables were recorded at baseline, 8 and 24 hours.

Proportions and continuous variables between *lower* and *higher* extracting devices were compared using χ^2 , Fisher exact tests, Student t-test or Wilcoxon rank-sum test. Continuous variables assessed at 8 and 24 hours were compared with previously described statistical analysis plans.²

RESULTS

Thirty-three patients (35%) were treated with the *lower* and 62 patients (65%) with the *higher* CO₂ extraction devices. At baseline, values of PaO₂/FiO₂ were higher and use of recruiting manoeuvres was less frequent in patients on *lower* vs *higher* CO₂ extraction devices (table 1) (p<0.05).

A 15.5 Fr catheter was used with the *lower* extraction device; an 18 (18–20) Fr catheter was used in patients on *higher* extraction devices (p=0.0001). At 12 hours after inclusion, doses of heparin and activated partial thromboplastin time ratio were similar between lower and higher extraction devices (21 000 (18 000; 27 950) vs 20 000 (14 000; 26 400), p=0.425 and 49.1±14.9 vs 57.6±21.6, p=0.074, respectively).

Respiratory rate and minute ventilation were higher in patients on the *lower* versus *higher* extraction devices (p<0.001) (figure 1). Time course of ventilator and blood gas parameters are shown in table 1. Compared with baseline, P_{PLAT} decreased by 10%–20% in both *lower* and *higher* extraction groups (p<0.001), and at 24 hours was significantly lower in patients treated with *lower* than in patients with *higher* extraction devices (p=0.003). Compared with baseline, PaCO₂ decreased at 8 and 24 (p<0.01) hours in patients treated with the *higher* extraction devices while it increased at 8 hours in patients treated with

Table 1 Time course of ventilator settings and blood gas analysis

	Baseline		8 hours		24 hours	
	Lower CO ₂ extraction (N=33)	Higher CO ₂ extraction (N=62)	Lower CO ₂ extraction (N=33)	Higher CO ₂ extraction (N=62)	Lower CO ₂ extraction (N=33)	Higher CO ₂ extraction (N=62)
P _{PLAT} (cmH ₂ O)	26.7±2.81	26.7±3.30	23.6±2.70†	24.3±3.96‡	21.9±3.15‡	24.4±4.03§
PEEP (cmH ₂ O)	13.58±3.73	13.55±3.77	13.84±3.11‡	14.54±3.88†	12.96±3.23	14.16±4.15†
Driving pressure (cmH ₂ O)	13.2±4.13	13.2±4.15	9.67±3.35‡	9.65±4.08‡	8.93±3.78†	10.4±4.49§
PaO ₂ /FIO ₂	185±57.1	159±66.9*	197±66.2	154±61.5*	198±62.9	153±56.3*
PaCO ₂ (mm Hg)	45.9±9.09	49.0±9.72	52.5±13.8†	44.8±9.28*†	49.0±13.6	45.5±8.33†
pH	7.33±0.09	7.35±0.09	7.30±0.09	7.40±0.08*†	7.35±0.08	7.41±0.07*†

Data are mean±SD.

**p*<0.05 lower vs higher CO₂ extraction.

†*p*≤0.01 vs baseline.

‡8 missing values.

§5 missing values.

PaCO₂, arterial PCO₂; PaO₂/FIO₂, arterial to inspiratory O₂ fraction; P_{PLAT}, end-inspiratory plateau pressure; PEEP, positive end-expiratory pressure.

the lower extraction system (*p*=0.01). PaCO₂ at 8 hours was lower with the *higher* than with the *lower* extraction system (*p*=0.008).

Percentage of patients reaching a V_T of 4 mL/kg PBW was 55% and 64% with the *lower* versus 90% and 92% with *higher* extraction devices at 8 and 24 hours, respectively (*p*<0.001).

Two severe adverse events were attributed to ECCO₂R (right frontal massive parenchymal haematoma with the *lower* and pneumothorax at insertion cannula in the internal jugular vein with the *higher* extraction devices). Percentage of patients experiencing

ECCO₂R-related adverse events was 48% with the *lower* and 34% with the *higher* extraction devices (*p*=0.242). Percentage of patients experiencing episodes of haemolysis and bleeding was higher with *lower* than with *higher* extraction devices (*p*<0.05) (table 2).

DISCUSSION

Analysis of the SUPERNOVA trial suggests that systems using higher flow (800–1000 mL/min) and a larger membrane (1.30 m²) are more effective in facilitating ultraprotective ventilator settings than using lower flow (<500 mL/min) and a smaller membrane (0.59 m²). Since there is no evidence of a safe upper limit for



Figure 1 Time course of respiratory variables. **p*<0.001 lower vs higher CO₂ extraction; #*p*<0.01 vs baseline.

Table 2 Numbers of patients experiencing ECCO₂R-related adverse events occurring between enrolment and day 28

Patients experiencing ECCO ₂ R-related adverse events n (%)	Lower CO ₂ extraction (N=33)	Higher CO ₂ extraction (N=62)
Mechanical		
Lung clotting membranes	3 (9)	10 (16)
Leading to circuit change	1 (3)	5 (8)
Leading to ECCO ₂ R discontinuation	2 (6)	5 (8)
Pump malfunction	2 (6)	1 (2)
Catheter displacement	2 (6)	0 (0)
Clinical		
Haemolysis	7 (21)	4 (6)*
Bleeding	9 (27)	4 (6)†
Related to cannula insertion	2 (6)	1 (2)
At cannula site	6 (18)	1 (2)*
Significant	3 (9)	3 (5)
Infectious complications	2 (6)	0 (0)
Thrombocytopenia	4 (12)	8 (13)
Hypofibrinogenemia	0 (0)	2 (3)

**p*<0.05.

†*p*<0.01.

#Haemolysis: serum-free haemoglobin ≥100 mg/L or haematocrit reduction not related to haemorrhage or other causes of blood loss, jaundice, haemoglobinuria, impaired renal function. Hypofibrinogenemia: fibrogen <1.5 g/L. Significant bleeding: any bleeding event requiring administration of 1 U of packed red cells. Thrombocytopenia: platelet count below 50×10⁹/L. ECCO₂R, extracorporeal carbon dioxide removal.

protective ventilator settings,⁵ outcomes may be improved by aggressively lowering V_T using devices that can remove more CO_2 , allowing lower respiratory rates, which were shown to be lung protective⁶ by decreasing mechanical power.⁷ It should be acknowledged that clearance and total amount of CO_2 removed by ECCO₂R with *lower* and *higher* extraction devices were not quantified.

Fitzgerald and coworkers recently performed a comprehensive systematic review that included 14 studies with 495 patients treated with ECCO₂R and found that complication rates ranged from 0% to 25%.⁸ Clotting/membrane malfunction, bleeding and increasing the requirement for blood transfusion were the most common complications.⁸ We have found that, although the *lower* extraction device used smaller cannulas and lower blood flow than the ones used with *higher* extraction devices, the percentage of patients with haemolysis and bleeding episodes was significantly higher in the former (table 2). Moreover, it should be noted that heparose and activated partial thromboplastin time ratio were similar between *lower* and *higher* extraction devices. This observation may be particularly relevant since (1) the balance between excessive anticoagulation (bleeding, haemolysis) and insufficient anticoagulation (clotting) is crucial for the safety and feasibility of ECCO₂R, and (2) the importance of monitoring coagulation during ECCO₂R is confirmed. Moreover, since in the present study contraindications for systemic anticoagulation and bleeding disorders were observed in 30% of patients,² feasibility and safety of randomised clinical trials using *lower* CO_2 extraction devices may be problematic.

In conclusion, these data suggest that reductions of V_T to 4 mL/kg and of P_{PLAT} to ≤ 25 of cmH_2O are consistently achievable only

with the *higher* extraction devices. Future randomised clinical trials assessing the overall benefit and harm of ultraprotective ventilation should be carried out with ECCO₂R devices equipped with a larger membrane lung and blood flows between 800 and 1000 mL/min.

Funding This study was supported by the European Society of Intensive Care Medicine (ESICM).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 Ranieri VM, Brodie D, Vincent J-L. Extracorporeal organ support: from technological tool to clinical strategy supporting severe organ failure. *JAMA* 2017;318.
- 2 Combes A, Fanelli V, Pham T, *et al.* Feasibility and safety of extracorporeal CO_2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. *Intensive Care Med* 2019;45:592–600.
- 3 Ranieri VM, Rubenfeld GD, Thompson BT, *et al.* Acute respiratory distress syndrome: the Berlin definition. *JAMA* 2012;307.
- 4 Mercat A, Richard J-CM, Vielle B, *et al.* Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 2008;299:646–55.
- 5 Sahetya SK, Sahetya SK, Sahetya SK, *et al.* 50 years of research in ARDS: tidal volume selection in the acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2017.
- 6 Grasso S, Stripoli T, Mazzone P, *et al.* Low respiratory rate plus minimally invasive extracorporeal CO_2 removal decreases systemic and pulmonary inflammatory mediators in experimental acute respiratory distress syndrome. *Crit Care Med* 2014;42:e451–60.
- 7 Gattinoni L, Tonetti T, Cressoni M, *et al.* Ventilator-related causes of lung injury: the mechanical power. *Intensive Care Med* 2016;42:1567–75.
- 8 Fitzgerald M, Millar J, Blackwood B, *et al.* Extracorporeal carbon dioxide removal for patients with acute respiratory failure secondary to the acute respiratory distress syndrome: a systematic review. *Crit Care* 2014;18:222.